Latest Conference Articles

In patients with pre-immune checkpoint inhibitor-naïve advanced melanoma, treatment with the combination of lifileucel plus pembrolizumab, compared to pembrolizumab alone, increased the overall response rate.

Data from the ongoing escalation and expansion trial CTNO1552101 showed promising results for the use of TN0155 in adults with advanced solid tumors.

Amivantamab in combination with lazertinib led to responses in more than a third of patients with EGFR-mutant non–small cell lung cancer who had progressed on treatment with osimertinib but had not received chemotherapy.

Continued efficacy is seen with nivolumab and ipilimumab plus 2 cycles of versus chemotherapy alone for patients with advanced non–small cell lung cancer.

Across several previously unreported subgroups of patients with advanced urothelial cancer who have progressed on first-line platinum-containing chemotherapy avelumab as frontline maintenance plus best supportive care demonstrated a survival benefit compared with BSC alone.

Sustained overall survival and progression-free survival benefits was confirmed following long-term treatment with durvalumab following chemoradation in patients with unresectable stage 3 non-small cell lung cancer whose disease had not progressed after platinum-based concurrent chemoradiotherapy.

Median duration of response was doubled with tivozanib compared with sorafenib in patients with metastatic renal cell carcinoma.

After 4 years of treatment with the combination of nivolumab and ipilimumab, the therapy showed durable, long-term overall survival benefit compared with chemotherapy in patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.

Mobocertinib, elicited rapid, deep, and durable responses and demonstrated a tolerable safety profile in patients with platinum-pretreated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer in a phase 1/2 study.

In a pharmacokinetic analysis of the first 15 patients in the phase 2 TBCRC049 study, researchers saw the first evidence for concentrations of tucatinib and ONT-993 in the cerebral spinal fluid of patients with HER2+ metastatic breast cancer with newly diagnosed leptomeningeal metastasis.

In patients with metastatic castration-resistant prostate cancer treated in a phase 1/2a study, the HPN424, a tri-specific half-life extended prostate-specific membrane antigen-targeting T cell engager was well tolerated and demonstrated antitumor activity.

One infusion of ciltacabtagene autoleucel lead to early and deep responses in a cohort of patients previously treated for relapsed/refractory multiple myeloma, according to findings the phase 2 CARTITUDE-2 study.

Pembrolizumab plus concurrent chemoradiation therapy continues to demonstrate promising antitumor activity in patients with unresectable, locally advanced, stage III non–small cell lung cancer.

Men with nonmetastatic castration-resistant prostate cancer tolerated treatment with darolutamide well, according to findings from the phase 3 ARAMIS trial.

In the phase 1/2 ARROW study, pralsentinib was found to be well-tolerated and showed durable responses as treatment of patients with RET fusion-positive non-small cell lung cancer, including those who were not eligible for platinum-based therapy.

Long-term follow-up data from the KarMMa trial found that treatment with the chimeric antigen receptor T-cell therapy, idecabtagene vicleucel, continues to demonstrate improved survival among heavily pretreated patients with relapsed/refractory multiple myeloma.

Patients with advanced gastrointestinal stromal tumor after receiving fourth-line therapy had extended progression-free survival when given an intra-patient dose escalation of ripretinib to 150 mg twice a day following progression.

In patients with ovarian cancer and BRCA mutations who were enrolled in 3 different trials, maintenance treatment with niraparib improved progression-free survival compared with placebo with no new safety signals.

In women with locally advanced cervical cancer, administering adjuvant chemotherapy following standard cisplatin-based chemoradiation did not improve survival outcomes, according to findings from the phase 3 OUTBACK trial.

Data from the phase 3 KEYNOTE-564 trial presented in a press briefing ahead of the 2021 ASCO Annual Meeting showed that adjuvant pembrolizuumab achieved significant disease-free survival improvement compared with placebo.

LuPSMA added to standard of care led to a nearly 40% reduction in the risk of death versus standard of care alone in the phase 3 VISION study.

For patients with PD-L1 positive non-small cell lung cancer, qdjuvant treatment with atezolizumab (Tecentriq) led to a significant improvement in disease-free survival (DFS) vs best supportive care.

For the past 17 years, HPV-related cervical cancer has been declining, however, other tumors related to the virus continue to remain steady.

Improved outcomes for younger African American patients is associated with increased prostate-specific antigen screening.

Policies may be needed to expand Medicaid access to patients, after investigators found worse long-term survival outcomes for patients who lived in states with lower income eligibility rather than higher income eligibility.

For patients with metastatic breast cancer, research suggests that utilizing a multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data may be feasible and better than DNA sequencing alone.

Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer, according to findings from a phase 2 trial presented in a poster at the American Association for Cancer Research Annual Meeting 2021.

More than half of patients with T790M-positive non-small cell lung cancer had a response to the third generation EGFR TKI D-0316 in a phase 2 study.

In the phase 2 C-144-01 trial, patients had durable responses to treatment with the tumor-infiltrating lymphocyte lifileucel after more than 28 months of follow-up.

For the treatment of patients with HER2-amplified gastric cancers in addition to those with HER2 moderate-, low-, and non-expressing disease, trastuzumab deruxtecan has shown to be an effective therapeutic option.